Gain an expansive view of your solid tumor samples by targeting 523 cancer-related genes using the TruSight Oncology 500 tissue. Not only does this assay identify all relevant variants (SNVs, insertions, deletions, CNVs, gene fusions, and transcript variants) across various tumor types, but it also reports tumor mutational burden (TMB) score and microsatellite instability (MSI) status.
Our comprehensive genomic panel has advantages over individual biomarker assays in its ability to detect multiple biomarkers with one test, saving time, money, and samples. Q2 can meet your profiling needs by leveraging trusted technology from Illumina® in combination with our global laboratory network and expert support team.
Obtain full exon coverage of 522 genes using as little as 40ng of FFPE DNA and RNA input.
Gain insight into TMB score and MSI status in addition to variant calls. TruSight Oncology 500 can reproducibly assess TMB and reliably determine TMB-H, making it a competitive offering for TMB assessment.
Obtain a high-resolution view of variants enabled by TSO500’s hybrid-capture chemistry and unique molecular indices.
Detect multiple biomarkers with a single assay to save time, money, and samples.
Our centralized scientific operational oversight combined with our global laboratory footprint enables comprehensive, large-scale trial support. We enable clinical development support irrespective of geography.
We work with you to understand your specific needs, and our team provides cost-effective recommendations from custom assay development to specialized bioinformatics support.
The TruSight Oncology 500 Tissue (TSO500 Tissue) can detect:
Our centralized, scientific, and operational oversight combined with our global laboratory footprint enables comprehensive, large-scale trial support. You will be supported every step of the way by our scientific project management team who will work with you to understand the most cost-effective recommendations to meet your specific needs. We are committed to transparency so you can feel confident in our promises of quality and timely delivery. We can expert support team can meet your research needs from nearly anywhere in the world with our genomic centers in the United States, China, United Kingdom, and Singapore.
The TruSight Oncology 500 (TSO500) for tissue assay employs a hybrid capture-based approach targeting 523 genes and leverages unique molecular indices to enable detection of low allele frequency...
Checkpoint inhibitor (CPI) therapy demonstrates a remarkable clinical benefit in many cancer types. However, the ability to successfully select patients who will benefit from CPIs is still limited....
At ASCO 2019, we presented a poster with Friends of Cancer Research (FOCR), highlighting their Tumor Mutational Burden (TMB) Harmonization Project. The goal of this Project is to harmonize TMB...